Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

The addition of subcutaneous daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy had a significant benefit on progression-free survival among patients with multiple myeloma.

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 390; no. 4; pp. 301 - 313
Main Authors: Sonneveld, Pieter, Dimopoulos, Meletios A., Boccadoro, Mario, Quach, Hang, Ho, P. Joy, Beksac, Meral, Hulin, Cyrille, Antonioli, Elisabetta, Leleu, Xavier, Mangiacavalli, Silvia, Perrot, Aurore, Cavo, Michele, Belotti, Angelo, Broijl, Annemiek, Gay, Francesca, Mina, Roberto, Nijhof, Inger S., van de Donk, Niels W.C.J., Katodritou, Eirini, Schjesvold, Fredrik, Sureda Balari, Anna, Rosiñol, Laura, Delforge, Michel, Roeloffzen, Wilfried, Silzle, Tobias, Vangsted, Annette, Einsele, Hermann, Spencer, Andrew, Hajek, Roman, Jurczyszyn, Artur, Lonergan, Sarah, Ahmadi, Tahamtan, Liu, Yanfang, Wang, Jianping, Vieyra, Diego, van Brummelen, Emilie M.J., Vanquickelberghe, Veronique, Sitthi-Amorn, Anna, de Boer, Carla J., Carson, Robin, Rodriguez-Otero, Paula, Bladé, Joan, Moreau, Philippe
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 25.01.2024
Subjects:
Adverse events
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - adverse effects
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bone marrow
Bortezomib
Bortezomib - administration & dosage
Bortezomib - adverse effects
Cancer therapies
CD38 antigen
Death
Dexamethasone
Dexamethasone - administration & dosage
Dexamethasone - adverse effects
Disease Progression
Hematology
Humans
Immunotherapy
Induction therapy
Inhibitor drugs
Lenalidomide - administration & dosage
Lenalidomide - adverse effects
Leukemia
Lymphoma
Minimal residual disease
Monoclonal antibodies
Multiple myeloma
Multiple Myeloma - drug therapy
Neutropenia
Oncology
Risk assessment
Survival
Targeted cancer therapy
Thrombocytopenia
Transplantation
Treatments in Oncology
ISSN:0028-4793, 1533-4406, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The addition of subcutaneous daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy had a significant benefit on progression-free survival among patients with multiple myeloma.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2312054